Highlights Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Real-time Estimate Cboe BZX Other stock markets 10:05:16 2024-09-10 EDT			5-day change	1st Jan Change
33.84 ^USD	-0.21%		-2.58%	+16.85%

09-04	Transcript : Supernus Pharmaceuticals, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-04-2024 04:30 PM
08-19	Sector Update: Health Care Stocks Edge Higher Premarket Monday	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sector Update: Health Care Stocks Edge Higher Premarket Monday	08-19	MT
Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA	08-19	CI
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q2 Revenue $168.3M, vs. Street Est of $148.9M	08-06	MT
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-06	CI
Supernus Pharmaceuticals, Inc. Raises Financial Guidance for the Full Year 2024	08-06	CI
Supernus Resubmits New Drug Application for Parkinson's Treatment Device	08-01	DJ
Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study	05-23	MT
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M	05-08	MT
Supernus Pharmaceuticals, Inc. Seeks M&A	05-08	CI
Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024	05-08	CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America	05-07	MT
M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Licensing Agreement with Supernus for Qelbree® (Viloxazine Xr) in Latin America	05-07	CI
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830	04-08	CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	04-08	RE
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	02-27	CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-27	CI
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q4 Revenue $164.3M, vs. Street Est of $155M	02-27	MT
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27	CI
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents	02-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Highlights

Filters